AP303 not checked

Alebund Pharmaceuticals

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Diabetic Kidney Disease
Main trialPhase 1
“The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.”In the company’s words, NCT06666283 on ClinicalTrials.gov

Other drugs for Diabetic Kidney Disease

All 12 drugs for Diabetic Kidney Disease

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 25 Sep 2025 A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
Phase 1Completed 21 Jul 2023 A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects
Phase 1Completed 13 May 2024 A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow AP303

Following is part of Solo: you see every change to AP303 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in